Physician profile
Charles A Walker
NPI 1144360785
$632.36
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $46.71 · 2021: $76.23 · 2023: $50.90 · 2024: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $240.21 | 2019-2024 | Belbuca, Xtampza |
| Biodelivery Sciences International, INC. | $63.45 | 2019-2021 | |
| Daiichi Sankyo INC. | $57.98 | 2019 | |
| Scilex Pharmaceuticals INC. | $48.20 | 2020-2024 | |
| Boston Scientific Corporation | $44.27 | 2024 | |
| Protega Pharmaceutials INC | $39.44 | 2024 | Roxybond |
| Alnylam Pharmaceuticals INC. | $39.32 | 2024 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.29 | 2019 | |
| Tersera Therapeutics LLC | $18.17 | 2023 | Prialt |
| Avanos Medical | $17.39 | 2023 | Generator |
| Virtus Pharmaceuticals LLC | $16.00 | 2021 | |
| Averitas Pharma INC. | $15.30 | 2024 | Qutenza |
| Sentynl Therapeutics, INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.